Christine Navarro
Biographic Data
| ID | 7450013 |
|---|---|
| NAME | Christine Navarro |
| GIVEN NAMES | Christine |
| FAMILY NAME | Navarro |
| SIGNATURE | NAVARRO C |
| AFFILIATIONS | University of Ottawa |
| ORCID | 0009-0008-1660-6169 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2004 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada
In May 2022, an outbreak of mpox emerged in Canada. In June 2022, the province of Ontario began offering first doses of a 2-dose regimen of Modified Vaccinia Ankara–Bavaria Nordic (MVA-BN) to those at high risk of exposure. Second doses became available in September 2022. To help increase dose 2 access and uptake, we sought to understand how individuals who received 2 doses differed from those who received only 1 dose. We conducted a cross-sectio…
Two Listeria monocytogenes outbreaks in a cancer centre
When procuring on-site food premises, healthcare facilities and institutions serving individuals with immuno-compromising conditions should consider the potential health risk of foods available to their patient population
Prevalence and factors related to public injecting in Ottawa, Canada
No prominent works on this page.
Prevalence and factors related to public injecting in Ottawa, Canada
Two Listeria monocytogenes outbreaks in a cancer centre
When procuring on-site food premises, healthcare facilities and institutions serving individuals with immuno-compromising conditions should consider the potential health risk of foods available to their patient population
Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada
In May 2022, an outbreak of mpox emerged in Canada. In June 2022, the province of Ontario began offering first doses of a 2-dose regimen of Modified Vaccinia Ankara–Bavaria Nordic (MVA-BN) to those at high risk of exposure. Second doses became available in September 2022. To help increase dose 2 access and uptake, we sought to understand how individuals who received 2 doses differed from those who received only 1 dose. We conducted a cross-sectio…
Public health (3 works) · Confidence interval (2 works) · Environmental health (2 works) · Medicine (2 works) · Outbreak (2 works) · Biology (1 work) · Casual (1 work) · Demography (1 work) · Demography (1 work) · Family medicine (1 work)